[go: up one dir, main page]

ZA200104899B - Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. - Google Patents

Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. Download PDF

Info

Publication number
ZA200104899B
ZA200104899B ZA200104899A ZA200104899A ZA200104899B ZA 200104899 B ZA200104899 B ZA 200104899B ZA 200104899 A ZA200104899 A ZA 200104899A ZA 200104899 A ZA200104899 A ZA 200104899A ZA 200104899 B ZA200104899 B ZA 200104899B
Authority
ZA
South Africa
Prior art keywords
polymer
set forth
pharmaceutically active
active molecule
patient
Prior art date
Application number
ZA200104899A
Other languages
English (en)
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ZA200104899B publication Critical patent/ZA200104899B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
ZA200104899A 1998-12-16 2001-06-14 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. ZA200104899B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
ZA200104899B true ZA200104899B (en) 2002-09-16

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200104899A ZA200104899B (en) 1998-12-16 2001-06-14 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.

Country Status (35)

Country Link
EP (1) EP1140026B1 (bg)
JP (1) JP4759141B2 (bg)
KR (1) KR100707710B1 (bg)
CN (1) CN1195497C (bg)
AP (1) AP1769A (bg)
AR (1) AR021652A1 (bg)
AT (1) ATE303795T1 (bg)
AU (1) AU770673B2 (bg)
BG (1) BG65500B1 (bg)
BR (1) BR9916276A (bg)
CA (1) CA2355077C (bg)
CR (1) CR6424A (bg)
CZ (1) CZ301947B6 (bg)
DE (1) DE69927177T2 (bg)
DK (1) DK1140026T3 (bg)
EA (1) EA004502B1 (bg)
EE (1) EE200100314A (bg)
ES (1) ES2245128T3 (bg)
HK (1) HK1041645B (bg)
HR (1) HRP20010446A2 (bg)
HU (1) HU226586B1 (bg)
ID (1) ID28909A (bg)
IL (2) IL143761A0 (bg)
ME (2) ME00066B (bg)
NO (1) NO20012981L (bg)
NZ (1) NZ511962A (bg)
OA (1) OA11728A (bg)
PL (1) PL196822B1 (bg)
RS (1) RS50123B (bg)
SK (1) SK285812B6 (bg)
TR (1) TR200101759T2 (bg)
TW (1) TWI221418B (bg)
UA (1) UA73101C2 (bg)
WO (1) WO2000035423A1 (bg)
ZA (1) ZA200104899B (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
AU2002256694A1 (en) * 2001-03-20 2002-10-03 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
BR0209914A (pt) 2001-05-23 2004-04-06 Hexal Ag Produto homogeneizado para implantes e micropartìculas
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
EP1797871B1 (en) * 2004-09-21 2015-02-25 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
BR112022012260A2 (pt) * 2019-12-31 2022-08-30 Wanka Tanka Ltd Formulação plástica de liberação estendida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (bg) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
EP0528978B1 (en) * 1990-05-16 2002-10-16 Southern Research Institute Mikrocaspules for controlled release and their use to stimulate nerve fiber growth
DK0531410T3 (da) * 1990-06-01 1995-01-30 Merrell Dow Pharma (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm

Also Published As

Publication number Publication date
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
SK8282001A3 (en) 2001-11-06
IL143761A (en) 2006-08-01
CR6424A (es) 2004-02-26
AR021652A1 (es) 2002-07-31
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
ATE303795T1 (de) 2005-09-15
NO20012981D0 (no) 2001-06-15
KR20010082359A (ko) 2001-08-29
BR9916276A (pt) 2001-09-04
WO2000035423A9 (en) 2002-08-22
MEP19408A (en) 2010-06-10
TR200101759T2 (tr) 2001-12-21
HRP20010446A2 (en) 2002-06-30
YU41401A (sh) 2003-12-31
SK285812B6 (sk) 2007-08-02
BG105591A (bg) 2002-01-31
PL196822B1 (pl) 2008-02-29
CN1330536A (zh) 2002-01-09
TWI221418B (en) 2004-10-01
ME00066B (me) 2010-06-10
HK1041645B (zh) 2005-07-29
KR100707710B1 (ko) 2007-04-18
AU1742500A (en) 2000-07-03
CZ301947B6 (cs) 2010-08-11
CA2355077C (en) 2009-05-26
PL348233A1 (en) 2002-05-20
DK1140026T3 (da) 2006-01-02
AP1769A (en) 2007-08-22
EP1140026A1 (en) 2001-10-10
HUP0105048A3 (en) 2002-09-30
OA11728A (en) 2005-02-01
EE200100314A (et) 2002-08-15
ES2245128T3 (es) 2005-12-16
EA200100551A1 (ru) 2001-10-22
IL143761A0 (en) 2002-04-21
HK1041645A1 (en) 2002-07-19
EP1140026B1 (en) 2005-09-07
CA2355077A1 (en) 2000-06-22
UA73101C2 (en) 2005-06-15
NZ511962A (en) 2003-06-30
DE69927177D1 (de) 2005-10-13
EA004502B1 (ru) 2004-04-29
JP2002532408A (ja) 2002-10-02
BG65500B1 (bg) 2008-10-31
DE69927177T2 (de) 2006-06-08
HU226586B1 (en) 2009-04-28
NO20012981L (no) 2001-07-27
CZ20012157A3 (cs) 2001-09-12
AU770673B2 (en) 2004-02-26
AP2001002198A0 (en) 2001-09-30
RS50123B (sr) 2009-03-25
JP4759141B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
ZA200104899B (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
JP2818704B2 (ja) 徐放性組成物およびその製造方法
DE69332210T2 (de) Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung
US6455526B1 (en) Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US9242004B2 (en) Methods for preparing polymers having low residual monomer content
US5569467A (en) Process for the preparation of microballs and microballs thus obtained
KR102388870B1 (ko) 가소제로서의 아미노 당의 용도
Wang et al. A rapid method for creating drug implants: Translating laboratory‐based methods into a scalable manufacturing process
EP2054028B9 (en) Subcutaneous implants releasing an active principle over an extended period of time
GB2277915A (en) Production of microballs including a pharmaceutically active ingredient and a polymer
CN106074393B (zh) 一种注射用多肽类药物的缓释微球的制备
MXPA01005920A (es) Antagonista del receptor de serotonina encapsulada de polimero biodegradable y metodo para preparar el mismo
EP4527376A1 (en) Long-acting sustained-release preparation containing pramipexole and preparation method therefor
CA3231101A1 (en) Sustained-release microspheres comprising donepezil
ESLAMI et al. Preparation and characterization of estradiol valerate microspheres using biodegradable polymers
Islami et al. Preparation and Characterization of Estradiol Valerate Microspheres Using Biodegradable Polymers: Preparation of estradiol valerate microspheres